<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154580</url>
  </required_header>
  <id_info>
    <org_study_id>MCN-1</org_study_id>
    <nct_id>NCT03154580</nct_id>
  </id_info>
  <brief_title>Marijuana Cue-Reactivity &amp; Seeking Behavior in Regular Cannabis Users</brief_title>
  <acronym>MCN</acronym>
  <official_title>Marijuana Cue-Reactivity &amp; Seeking Behavior in Regular Cannabis Users: A Pilot Test of Glutamatergic Modulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to examine the relationship between marijuana reminders,
      or &quot;cues&quot;, craving for marijuana, and marijuana use. The principal investigator is also
      assessing whether N-acetylcysteine, can reduce marijuana craving or use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves three screening sessions that could last about 3 hours each.

      Part of this study will be conducted on an inpatient unit where the participant will live for
      4 straight nights.

      During the inpatient stay participants will participant in experimental sessions where they
      will be asked to smoke cigarettes containing either marijuana or placebo (a blank).
      Participants will be asked to take capsules that could contain N-acetylcysteine or placebo
      (blank).

      Participants will be asked to complete questionnaires and you will have your vital signs
      (blood pressure, heart rate) monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marijuana Craving Visual Analog Scale (VAS) (Self-report measure)</measure>
    <time_frame>Change is being assessed. Marijuana Craving VAS administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1250, 1310, 1320, 1330, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Marijuana Craving Questionnaire (Self-report measure)</measure>
    <time_frame>Change is being assessed. Marijuana Craving Quest.administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Marijuana Rating Form (Self-report measure)</measure>
    <time_frame>Change is being assessed. Marijuana Rating Form administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Effects Scale Visual Analog Scale (VAS) (Self-report measure)</measure>
    <time_frame>Change is being assessed. Subjective Effects Scale administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire of Smoking Urges (Self-report measure)</measure>
    <time_frame>Change is being assessed. Questionnaire is administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Marijuana Withdrawal Checklist</measure>
    <time_frame>Change is being assessed. Questionnaire is administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NAC Side Effect Checklist</measure>
    <time_frame>Change is being assessed. Questionnaire is administered at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure (physiological effects)</measure>
    <time_frame>Change is being assessed. Systolic blood pressure measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure (physiological effects)</measure>
    <time_frame>Change is being assessed. Diastolic blood pressure measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate (physiological effects)</measure>
    <time_frame>Change is being assessed. Heart rate measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Core-body temperature (physiological effects)</measure>
    <time_frame>Change is being assessed. Core-body temperature measured at baseline 0900, at 0930, 1000, 1030, 1100, 1230, 1345, 1400, 1430, 1500, 1530, and 1600.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Marijuana Abuse</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine 0mg X Cue Exposure (neutral)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine 0mg X Cue Exposure (marijuana)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine 2400mg X Cue Exposure (neutral)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine 2400mg X Cue Exposure (marijuana)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>Participants will receive 4 capsules at 11:15am on each experimental session day.</description>
    <arm_group_label>N-acetylcysteine 0mg X Cue Exposure (neutral)</arm_group_label>
    <arm_group_label>N-acetylcysteine 0mg X Cue Exposure (marijuana)</arm_group_label>
    <arm_group_label>N-acetylcysteine 2400mg X Cue Exposure (neutral)</arm_group_label>
    <arm_group_label>N-acetylcysteine 2400mg X Cue Exposure (marijuana)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be healthy individuals 21-55 year olds who use marijuana.

          -  Marijuana use will be verified by self-report and THC-positive urine samples.
             -Participants must meet DSM 5 criteria for Cannabis Use Disorder and be willing to
             participate in research but not seeking treatment.

        Exclusion Criteria:

          -  Candidates with the following conditions will be excluded:

          -  Serious psychiatric illness (e.g. psychotic or bipolar disorder

          -  Recent (past 5 years) suicide attempts

          -  Major depression that is not substance-induced)

          -  Substance Use Disorders (SUD) other than Cannabis or Nicotine Use Disorders and Mild
             Alcohol Use Disorder

          -  Neurological diseases (e.g. stroke, seizures)

          -  Cardiovascular problems (e.g. myocardial infarction, angina, systolic BP &gt;160 or &lt;95
             mmHg, diastolic BP &gt;95 mmHg, clinically abnormal ECG)

          -  Pulmonary diseases (e.g. asthma, TB)

          -  Systemic diseases (e.g. hepatitis, autoimmune, Cushing syndrome)

          -  Cognitive impairment (&lt;80 IQ)

          -  Past-month exposure to medications that increase study risk (e.g. toxicity to major
             organs, asthma inhalers)

          -  Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually
             active and not using (self-report) medically approved birth control measures
             (oral/depot contraceptives, IUD, condom/foam, sterilization, tubal ligation)

          -  Seeking treatment for a Substance Use Disorder.

          -  Individuals unable to give voluntary informed consent will be excluded. Applicants
             interested in treatment will be excluded from the study and referred to a treatment
             program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Lundahl, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wane State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Sulkowski, BS</last_name>
    <phone>313-993-3966</phone>
    <email>lsulkows@med.wayne.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tolan Park Medical Building</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Lundahl, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Leslie Lundahl</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

